Macrogenics (MGNX) Receivables - Other (2014 - 2015)
Macrogenics (MGNX) reported Receivables - Other of $900000.0 for Q3 2015, up 118.18% year-over-year from $412500.0 in Q3 2014, and up 12.5% quarter-over-quarter from $800000.0 in Q2 2015.
Macrogenics (MGNX) Receivables - Other (2014 - 2015) Analysis & Trends
Macrogenics (MGNX) has 2 years of Receivables - Other data on file, last reported at $900000.0 in Q3 2015.
- Receivables - Other for Q3 2015 came in at $900000.0, up 118.18% year-over-year; the trailing twelve-month figure through Sep 2015 was $900000.0 (up 118.18% YoY), and the FY2014 annual result was $500000.0, changed N/A from the prior year.
- Receivables - Other rose to $900000.0 in Q3 2015 per MGNX's latest filing, from $800000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $900000.0 in Q3 2015 and troughed at $0.6 in Q1 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Macrogenics | 260.14 Mn | 193.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 900,000.00 |
| Sep 30, 2015 | 900,000.00 |
| Jun 30, 2015 | 800,000.00 |
| Jun 30, 2015 | 800,000.00 |
| Mar 31, 2015 | 0.60 |
| Mar 31, 2015 | 0.60 |
| Dec 31, 2014 | 500,000.00 |
| Dec 31, 2014 | 500,000.00 |
| Sep 30, 2014 | 412,500.00 |
| Sep 30, 2014 | 412,500.00 |